Risk-adapted Therapy for Primary Acute Myeloid Leukemia (AML) in Adult Patients up to 70 Years Old
Latest Information Update: 30 Jun 2023
Price :
$35 *
At a glance
- Drugs Cytarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Idarubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 26 Jun 2023 Status changed from recruiting to completed.
- 17 Jun 2022 Results assessing outcome of FLT3mut AML treated with a risk-adapted protocol in two different time periods, mainly differentiated by the advent of midostaurin presented at the 27th Congress of the European Haematology Association
- 30 Jul 2021 Planned End Date changed from 1 Feb 2021 to 1 Oct 2021.